Avisa Diagnostics: World’s First Breath Test Designed to Detect & Monitor Pulmonary Infections

An Exclusive Behind-The-Scenes Look at Avisa Diagnostics Inc.’s Innovation

We invite you to join us for an exclusive look at Avisa Diagnostics’ innovative platform and how it is transforming healthcare.

Avisa is a clinical-stage medical device company developing the Avisa BreathTest™, (ABT), a novel drug/device combination biomarker technology platform. The Company has established clinical proof-of-concept through trials in cystic fibrosis, tuberculosis and community-acquired pneumonia, which demonstrated positive safety and clinical efficacy results.

There are 1.7 million patients on ventilators annually in the U.S, with 400,000 of these patients diagnosed with ventilator-associated pneumonia, resulting in a mortality rate of 30% to 50%.